Senate Bill S4054A

2017-2018 Legislative Session

Establishes the sickle cell treatment act of 2017; appropriation

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Senate Committee Finance Committee


  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions

Bill Amendments

co-Sponsors

2017-S4054 - Details

See Assembly Version of this Bill:
A5313
Current Committee:
Senate Finance
Law Section:
Appropriations
Laws Affected:
Amd §365, Soc Serv L; add Art 31 Title 4 §3126, Pub Health L
Versions Introduced in Other Legislative Sessions:
2013-2014: S6239
2015-2016: S3256
2019-2020: S2281, A6493

2017-S4054 - Summary

Furnishes preventive medicine to those with sickle cell, establishes prevention and treatment of sickle cell disease programs, and makes an appropriation thereto.

2017-S4054 - Sponsor Memo

2017-S4054 - Bill Text download pdf

                            
 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   4054
 
                        2017-2018 Regular Sessions
 
                             I N  S E N A T E
 
                             February 2, 2017
                                ___________
 
 Introduced  by Sens. SANDERS, DILAN, HAMILTON, LATIMER, PARKER, PERKINS,
   PERSAUD -- read twice and ordered printed,  and  when  printed  to  be
   committed to the Committee on Finance
 
 AN  ACT  to  amend the social services law and the public health law, in
   relation to establishing the sickle cell treatment act  of  2017;  and
   making an appropriation therefor
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. This act shall be known and may be  cited  as  the  "sickle
 cell treatment act of 2017".
   §  2.  Legislative findings. The legislature hereby finds and declares
 the following:
   (1) Sickle cell disease (SCD) is an inherited  disease  of  red  blood
 cells and is a major health problem in the United States.
   (2) Approximately 100,000 Americans have SCD with approximately 10% of
 SCD  patients residing in New York state (NYS).  In NYS, 1 in 1,146 live
 births have sickle cell disease, with 12% of  NYS  sickle  cell  disease
 births  in the Hispanic population. Higher birth rates for children with
 sickle cell disease in NYS occur in mothers born outside of  the  United
 States.    Approximately 1,000 American babies are born with the disease
 each year. SCD also is a global problem with  close  to  500,000  babies
 born annually with the disease.
   (3)  In the United States, SCD is most common in African-Americans and
 in those of Hispanic, Mediterranean, and Middle Eastern ancestry.  Among
 newborn  American  infants  nationally, SCD occurs in approximately 1 in
 500 African-Americans, 1 in 36,000 Hispanics, and  1  in  80,000  Cauca-
 sians.    In  NYS, sickle cell disease occurs in 1 in 230 live births to
 non-Hispanic black mothers, 1 in 2,320 births to Hispanic mothers and  1
 in 41,647 births to Caucasian mothers.
   (4)  More than 3,000,000 Americans, mostly African-Americans, have the
 sickle cell trait. These Americans are carriers of the sickle cell  gene
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
              

co-Sponsors

2017-S4054A (ACTIVE) - Details

See Assembly Version of this Bill:
A5313
Current Committee:
Senate Finance
Law Section:
Appropriations
Laws Affected:
Amd §365, Soc Serv L; add Art 31 Title 4 §3126, Pub Health L
Versions Introduced in Other Legislative Sessions:
2013-2014: S6239
2015-2016: S3256
2019-2020: S2281, A6493

2017-S4054A (ACTIVE) - Summary

Furnishes preventive medicine to those with sickle cell, establishes prevention and treatment of sickle cell disease programs, and makes an appropriation thereto.

2017-S4054A (ACTIVE) - Sponsor Memo

2017-S4054A (ACTIVE) - Bill Text download pdf

                            
 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  4054--A
 
                        2017-2018 Regular Sessions
 
                             I N  S E N A T E
 
                             February 2, 2017
                                ___________
 
 Introduced  by Sens. SANDERS, DILAN, HAMILTON, LATIMER, PARKER, PERKINS,
   PERSAUD, STAVISKY -- read twice and ordered printed, and when  printed
   to  be  committed to the Committee on Finance -- committee discharged,
   bill amended, ordered reprinted as amended  and  recommitted  to  said
   committee

 AN  ACT  to  amend the social services law and the public health law, in
   relation to establishing the sickle cell treatment act  of  2017;  and
   making an appropriation therefor
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. This act shall be known and may be  cited  as  the  "Sickle
 Cell Treatment Act of 2017".
   §  2.  Legislative findings. The legislature hereby finds and declares
 the following:
   (1) Sickle cell disease (SCD) is an inherited  disease  of  red  blood
 cells  and  the  CDC  (Centers for Disease Control) states that SCD is a
 major public health concern. Approximately  1,000  American  babies  are
 born  with the disease each year, while globally 500,000 babies are born
 annually with the disease.
   (2) Sickle cell disease affects approximately 100,000 Americans and is
 most common in African-Americans as well as those of Hispanic,  Mediter-
 ranean  and  Middle Eastern ancestry. Nationally, SCD occurs in approxi-
 mately 1:500 African-Americans, 1:36,000 Hispanics and  1:80,000  Cauca-
 sians.  However, in NYS (New York State) SCD occurs in 1:230 live births
 to non-Hispanic black mothers, 1:2,320 births to  Hispanic  mothers  and
 1:41,647 Caucasian mothers.
   (3)  Approximately  10% of SCD patients reside in NYS. In NYS, 1:1,146
 live births have sickle cell  disease,  with  12%  of  NYS  sickle  cell
 disease  births  in  the Hispanic population. Higher birth rates for SCD
 occur in mothers who were born outside of the US. In NYS,  approximately
 80% of sickle cell disease patients live in the NYC area.

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
              

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.